HC Wainwright Reiterates “Buy” Rating for Unicycive Therapeutics (NASDAQ:UNCY)

HC Wainwright restated their buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a report issued on Wednesday morning,Benzinga reports. HC Wainwright currently has a $4.00 target price on the stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a report on Friday, November 22nd. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $5.50.

Unicycive Therapeutics Trading Down 4.9 %

Unicycive Therapeutics stock opened at $0.74 on Wednesday. The stock has a 50 day moving average of $0.65 and a two-hundred day moving average of $0.49. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.82. The stock has a market capitalization of $76.81 million, a price-to-earnings ratio of -0.76 and a beta of 2.30.

Institutional Trading of Unicycive Therapeutics

Hedge funds have recently modified their holdings of the business. Walleye Capital LLC purchased a new stake in Unicycive Therapeutics during the third quarter worth about $2,040,000. Great Point Partners LLC acquired a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at approximately $3,491,000. Acuta Capital Partners LLC acquired a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at approximately $807,000. Virtu Financial LLC boosted its stake in shares of Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company’s stock worth $30,000 after acquiring an additional 62,881 shares in the last quarter. Finally, Bleakley Financial Group LLC acquired a new stake in shares of Unicycive Therapeutics in the 3rd quarter worth approximately $33,000. 40.42% of the stock is owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.